Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-00993-8
Abstract: We thank Aksan and colleagues for their interest in our recent article on the budgetary implications of using iron isomaltoside 1000 (IIM) relative to other intravenous (IV) iron formulations in patients with inflammatory bowel disease… read more here.
Keywords: bowel disease; patients inflammatory; inflammatory bowel; isomaltoside 1000 ... See more keywords